For Q1 FY2026 (ended March 31, 2026), 4D Molecular Therapeutics reported revenue of $3.0 million, a significant increase from the prior year, driven by collaboration revenue. Net loss widened to $68.8 million, with operating loss of $73.6 million, reflecting higher R&D and G&A expenses. Diluted EPS was -$1.01. Cash and cash equivalents stood at $72.5 million, with total equity of $451.8 million and no long-term debt.
•Revenue surged to $3.0M from near zero in Q1 FY2025, a 21,664% increase.
•Net loss expanded 43% to $68.8M, with operating loss up 37% to $73.6M.
•Cash position of $72.5M and equity of $451.8M; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company develops adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection For treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis.
Its portfolio also includes 4D-175 that is in preclinical stage for treating geographic atrophy, and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. Founded in 2013, the company is headquartered in EmeryVille, California.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company focused on developing adeno-associated virus (AAV) vectors using its proprietary Therapeutic Vector Evolution platform. The company designs targeted vectors for gene therapy applications. Its lead product candidate is 4D-150, designed for retinal vascular diseases such as wet age-related macular degeneration and diabetic macular edema, aiming to provide multi-year sustained anti-VEGF production via intravitreal injection. Another candidate, 4D-710, is in early-stage study for cystic fibrosis. Preclinical programs include 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency lung disease. The company operates in the Netherlands and the United States.
Where is 4D Molecular Therapeutics (FDMT) listed and in which currency?
4D Molecular Therapeutics is publicly traded on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol FDMT. Its shares are denominated in US dollars (USD), reflecting its primary listing in the United States. The company's headquarters are located in Emeryville, California, and it also has operations in the Netherlands.
What sector and industry does 4D Molecular Therapeutics (FDMT) belong to?
4D Molecular Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing gene therapies using proprietary AAV vector technology. Its work involves late-stage clinical development for retinal diseases and early-stage studies for other conditions like cystic fibrosis and lung disease, positioning it within the broader biotech landscape.
Where is 4D Molecular Therapeutics (FDMT) headquartered and what markets does it serve?
4D Molecular Therapeutics is headquartered in Emeryville, California, United States. The company also has operations in the Netherlands, indicating a presence in both North America and Europe. Its research and development activities target global markets, with a focus on retinal vascular diseases, cystic fibrosis, geographic atrophy, and alpha-1 antitrypsin deficiency lung disease. The company collaborates with Otsuka Pharmaceutical Co., Ltd., extending its reach in the pharmaceutical industry.
What are the main product candidates of 4D Molecular Therapeutics (FDMT)?
4D Molecular Therapeutics' lead product candidate is 4D-150, intended for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. It is designed to deliver sustained anti-VEGF production from the retina via a single intravitreal injection. Another candidate, 4D-710, is in early-stage development for cystic fibrosis. The preclinical pipeline includes 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency lung disease. The company also has a collaboration with Otsuka Pharmaceutical Co., Ltd. to advance its programs.